|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The ataxia-telangiectasia group D complementing gene, ATDC, is located at 11q23, where loss of heterozygosity (LOH) is frequently observed in many kinds of cancers including breast cancer.
|
16890201 |
2006 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accumulating evidence has suggested that the ataxia telangiectasia group D complementing (ATDC) gene is an emerging cancer-related gene in multiple human cancer types.
|
31168819 |
2019 |
|
Cerebrovascular accident
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
A genome-wide association study identifies a gene network of ADAMTS genes in the predisposition to pediatric stroke.
|
22990015 |
2012 |
|
Corneal Topography
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic variants near PDGFRA are associated with corneal curvature in Australians.
|
22969067 |
2012 |
|
Corneal Topography
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Genetic variants near PDGFRA are associated with corneal curvature in Australians.
|
22969067 |
2012 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Taken together, our findings suggested that TRIM29 played a crucial role in the progression and malignancy of TC, and silencing of TRIM29 exerted its antitumor effect by blocking P13K/AKT signaling pathway.
|
28098872 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accumulating evidence has suggested that the ataxia telangiectasia group D complementing (ATDC) gene is an emerging cancer-related gene in multiple human cancer types.
|
31168819 |
2019 |
|
Ataxia Telangiectasia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Ataxia-telangiectasia group D complementing gene (ATDC, also known as TRIM29), is highly expressed and drives tumor formation and invasion in human bladder cancers but the factor(s) regulating its expression in bladder cancer are unknown.
|
30643195 |
2019 |
|
Ataxia Telangiectasia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Here we describe a novel mouse model expressing ataxia telangiectasia group D complementing gene (ATDC, also known as TRIM29 [tripartite motif 29]) that, in the presence of oncogenic KRAS, accelerates pancreatic intraepithelial neoplasia (PanIN) formation and the development of invasive and metastatic cancers.
|
25593307 |
2015 |
|
Ataxia Telangiectasia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
The ataxia telangiectasia group D-complementing (ATDC) gene product, also known as TRIM29, is a member of the tripartite motif (TRIM) protein family.
|
20368352 |
2010 |
|
Ataxia Telangiectasia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Accumulating evidence has suggested that the ataxia telangiectasia group D complementing (ATDC) gene is an emerging cancer-related gene in multiple human cancer types.
|
31168819 |
2019 |
|
Breast Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The ataxia-telangiectasia group D complementing gene, ATDC, is located at 11q23, where loss of heterozygosity (LOH) is frequently observed in many kinds of cancers including breast cancer.
|
16890201 |
2006 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that TRIM29 acts as a tumor suppressor in breast cancer through its ability to inhibit TWIST1 and suppress EMT.
|
24950909 |
2014 |
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
This study establishes TRIM29 as a hypoxia-induced tumor suppressor gene and provides a novel molecular mechanism for ATM-dependent breast cancer suppression.
|
27535224 |
2016 |
|
Glioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
ATDC contributes to sustaining the growth and invasion of glioma cells through regulating Wnt/β-catenin signaling.
|
30929997 |
2019 |
|
mixed gliomas
|
0.300 |
Biomarker
|
disease |
CTD_human |
ATDC contributes to sustaining the growth and invasion of glioma cells through regulating Wnt/β-catenin signaling.
|
30929997 |
2019 |
|
Malignant Glioma
|
0.300 |
Biomarker
|
disease |
CTD_human |
ATDC contributes to sustaining the growth and invasion of glioma cells through regulating Wnt/β-catenin signaling.
|
30929997 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, TRIM29 knockdown significantly reduced cancer cell proliferation via notably inducing cell cycle arrest and cell apoptosis.
|
27430345 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Abnormal expression of tripartite motif-containing 29 (TRIM29) has been reported to promote tumorigenesis and predict poor prognosis in several human malignancies.
|
28098872 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Depletion of TRIM29 increased cancer cell migration and invasion; conversely, overexpression of TRIM29 suppressed these.
|
30389700 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRIM29 as a prognostic predictor for multiple human malignant neoplasms: a systematic review and meta-analysis.
|
29552313 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TRIM29 (ATDC) exhibits a contextual function in cancer, but seems to exert a tumor-suppressor role in breast cancer.
|
24950909 |
2014 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tripartite motif containing 29 (TRIM29) dysregulation serves an important function in the progression of numerous types of cancer, but its function in the prognosis of patients with gastric cancer remains unknown.
|
29556308 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, the current study found that TRIM29 knockdown suppressed cancer stem cell-like features of PDACs, which can be rescued by ISG15 independent of its conjugation function.
|
31501523 |
2020 |